Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Cash from Investing Activities (2017 - 2021)

Cogent Biosciences (COGT) has 3 years of Cash from Investing Activities data on record, last reported at -$433000.0 in Q4 2021.

  • For Q4 2021, Cash from Investing Activities changed N/A year-over-year to -$433000.0; the TTM value through Dec 2021 reached -$1.6 million, down 119.6%, while the annual FY2025 figure was -$399.5 million, 1143.8% down from the prior year.
  • Cash from Investing Activities reached -$433000.0 in Q4 2021 per COGT's latest filing, up from -$1.2 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $15.0 million in Q4 2018 and bottomed at -$41.4 million in Q2 2018.
  • Average Cash from Investing Activities over 3 years is $1.1 million, with a median of $3.1 million recorded in 2018.
  • The widest YoY moves for Cash from Investing Activities: up 152.32% in 2019, down 100.09% in 2019.
  • A 3-year view of Cash from Investing Activities shows it stood at $15.0 million in 2018, then tumbled by 100.09% to -$13000.0 in 2019, then tumbled by 3230.77% to -$433000.0 in 2021.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$433000.0 in Q4 2021, -$1.2 million in Q3 2021, and -$13000.0 in Q4 2019.